Poolbeg Pharma has announced a positive interim safety review from the TOPICAL clinical trial of POLB 001, with the study recommended to continue as planned and no changes required to the protocol. Recruitment is continuing at UK clinical sites, with further patients expected to enrol and additional sites set to be activated as the company progresses the trial and generates further data for prospective partners.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
